XML 34 R22.htm IDEA: XBRL DOCUMENT
v3.20.2

Notes Payable | 9 Months Ended
--- | ---
Sep. 30, 2020
Receivables [Abstract] |
Notes payable |
| 16. | Notes payable
Notes payable as of December 31, 2019 and September 30, 2020 consist of the following:
|  | December 31, |  |  | September 30, |
|  | 2019 |  |  | 2020 |
Notes payable, net of debt discount |  | $ | 2,846,736 |  |  | $ | 1,614,583 |
Note I On July 24, 2019, the Company entered into a securities purchase agreement with Atlas Sciences, LLC (the "Lender"), pursuant to which the Company issued a promissory note (the "Note I") to the Lender. The Note has an original principal amount of $1,395,000, bears interest at a rate of 10% per annum and will mature 12 months after the issuance, unless earlier paid or redeemed in accordance with its terms. The Company received proceeds of $1,250,000 after an original issue discount of $125,000 and payment of Lender's expenses of $20,000. Beginning on the date that is six months after July 24, 2019, Lender shall have the right, exercisable at any time in its sole and absolute discretion, to redeem any amount of this Note up to $250,000.00 per calendar month by providing written notice to Borrower. The Company recorded the $125,000 as debt discount and is being amortized as interest expense over 12 months period. The Company did not assign any value to the redemption feature of the Note because the redemption of the Note has no value on the redemption portion as of September 30, 2020. On January 27, 2020, the Company entered into an exchange agreement (the "First Exchange Agreement") with Atlas Sciences, LLC (the "Lender"), pursuant to which the Company and the Lender agreed to (i) partition a new promissory note in the original principal amount equal to $100,000 (the "Partitioned Promissory Note) from the outstanding balance of certain promissory note that the Company issued to the Lender on July 24, 2019, which has an original principal amount of $1,395,000, and (ii) exchange the Partitioned Promissory Note for the issuance of 160,256 shares of the Company's common stock, par value $0.001 per share to the Lender. On February 20, 2020, the Company entered into a second exchange agreement (the "Second Exchange Agreement") with Atlas Sciences, LLC (the "Lender"), pursuant to which the Company and the Lender agreed to (i) partition a new promissory note in the original principal amount equal to $100,000 (the "Partitioned Promissory Note") from the outstanding balance of certain promissory note that the Company issued to the Lender on July 24, 2019, which has an original principal amount of $1,395,000, and (ii) exchange the Partitioned Promissory Note for the issuance of 207,641 shares of the Company's common stock, par value $0.001 per share to the Lender. On April 28, 2020, the Company entered into a third exchange agreement (the "Third Exchange Agreement") with Atlas Sciences, LLC (the "Lender"), pursuant to which the Company and the Lender agreed to (i) partition a new promissory note in the original principal amount equal to $100,000 (the "Partitioned Promissory Note") from the outstanding balance of certain promissory note that the Company issued to the Lender on July 24, 2019, which has an original principal amount of $1,395,000, and (ii) exchange the Partitioned Promissory Note for the issuance of 312,500 shares of the Company's common stock, par value $0.001 per share to the Lender. On June 8, 2020, the Company entered into a fourth exchange agreement (the "Fourth Exchange Agreement") with Atlas Sciences, LLC (the "Lender"), pursuant to which the Company and the Lender agreed to (i) partition a new promissory note in the original principal amount equal to $100,000 (the "Partitioned Promissory Note") from the outstanding balance of certain promissory note that the Company issued to the Lender on July 24, 2019, which has an original principal amount of $1,395,000, and (ii) exchange the Partitioned Promissory Note for the issuance of 271,739 shares of the Company's common stock, par value $0.001 per share to the Lender. On June 10, 2020, the Company entered into a fifth exchange agreement (the "Fifth Exchange Agreement") with Atlas Sciences, LLC (the "Lender"), pursuant to which the Company and the Lender agreed to (i) partition a new promissory note in the original principal amount equal to $150,000 (the "Partitioned Promissory Note") from the outstanding balance of certain promissory note that the Company issued to the Lender on July 24, 2019, which has an original principal amount of $1,395,000, and (ii) exchange the Partitioned Promissory Note for the issuance of 407,609 shares of the Company's common stock, par value $0.001 per share to the Lender. On July 6, 2020, the Company entered into a Sixth exchange agreement (the "Sixth Exchange Agreement") with Atlas Sciences, LLC (the "Lender"), pursuant to which the Company and the Lender agreed to (i) partition a new promissory note in the original principal amount equal to $250,000 (the "Partitioned Promissory Note") from the outstanding balance of certain promissory note that the Company issued to the Lender on July 24, 2019, which has an original principal amount of $1,395,000, and (ii) exchange the Partitioned Promissory Note for the issuance of 461,595 shares of the Company's common stock, par value $0.001 per share to the Lender. On July 29, 2020, the Company entered into a Seventh exchange agreement (the "Seventh Exchange Agreement") with Atlas Sciences, LLC (the "Lender"), pursuant to which the Company and the Lender agreed to (i) partition a new promissory note in the original principal amount equal to $365,000 (the "Partitioned Promissory Note") from the outstanding balance of certain promissory note that the Company issued to the Lender on July 24, 2019, which has an original principal amount of $1,395,000, and (ii) exchange the Partitioned Promissory Note for the issuance of 576,802 shares of the Company's common stock, par value $0.001 per share to the Lender. On October 12, 2020, the Company entered into an amendment to Promissory Notes (the "Amendment") with Atlas Sciences, LLC (the Lender), pursuant to which the Lender has the right at any time until the outstanding balance of the Notes has been paid in full, at its election, to convert all or any portion of the outstanding balance of the Notes into shares of common stock of the Company. The conversion price for each conversion will be calculated pursuant to the following formula: 80% multiplied by the lowest closing price of the Company common stock during the ten (10) trading days immediately preceding the applicable conversion (the "Conversion Price"). Notwithstanding the foregoing, in no event will the Conversion Price be less than $1.00. According to the amendment, on October 13, 2020, the Company exchanged $371,275 in principal and coupon interests under the Note I for the issuance of 229,750 shares of the Company's common stock, par value $0.001 per share to the Lender. As of the date of this report, the Company has fully repaid the principal and coupon interests of Note I. The Company recorded $23,630 and $26,371 to interest expense from the amortization of debt discount and coupon interest, respectively, for the three and nine months ended September 30, 2019. The Company recorded $5,903 and $9,235 to interest expense from the amortization of debt discount and coupon interest for Note I, respectively, for the three months ended September 30, 2020. The Company recorded $69,097 and $68,497 to interest expense from the amortization of debt discount and coupon interest for Note I, respectively, for the nine months ended September 30, 2020. As of December 31, 2019 and September 30, 2020, accrued coupon interest of $62,387 and $130,884 on the Note I was included in other payables and accruals (note 13), respectively. Note II On December 30, 2019, the Company entered into a securities purchase agreement with Atlas Sciences, LLC (the "Lender"), pursuant to which the Company issued a promissory note (the "Note II") to the Lender. The Note has an original principal amount of $1,670,000, bears interest at a rate of 10% per annum and will mature 12 months after the issuance, unless earlier paid or redeemed in accordance with its terms. The Company received proceeds of $1,500,000 after an original issue discount of $150,000 and payment of Lender's expenses of $20,000. Beginning on the date that is six months after June 30, 2020, Lender shall have the right, exercisable at any time in its sole and absolute discretion, to redeem any amount of this Note up to $250,000.00 per calendar month by providing written notice to Borrower. The Company recorded the $150,000 as debt discount and is being amortized as interest expense over 12 months period. The Company did not assign any value to the redemption feature of the Note because the redemption of the Note has no value on the redemption portion as of December 31, 2019 and September 30, 2020. On July 8, 2020, the Company entered into a First exchange agreement for Note II (the "First Exchange Agreement- Note II") with Atlas Sciences, LLC (the "Lender"), pursuant to which the Company and the Lender agreed to (i) partition a new promissory note in the original principal amount equal to $250,000 (the "Partitioned Promissory Note") from the outstanding balance of certain promissory note that the Company issued to the Lender on December 30, 2019, which has an original principal amount of $1,670,000, and (ii) exchange the Partitioned Promissory Note for the issuance of 453,161 shares of the Company's common stock, par value $0.001 per share to the Lender. On October 12, 2020, the Company entered into an amendment to Promissory Notes (the "Amendment") with Atlas Sciences, LLC (the Lender), pursuant to which the Lender has the right at any time until the outstanding balance of the Notes has been paid in full, at its election, to convert all or any portion of the outstanding balance of the Notes into shares of common stock of the Company. The conversion price for each conversion will be calculated pursuant to the following formula: 80% multiplied by the lowest closing price of the Company common stock during the ten (10) trading days immediately preceding the applicable conversion (the "Conversion Price"). Notwithstanding the foregoing, in no event will the Conversion Price be less than $1.00. According to the amendment, on October 13, 2020, the Company exchanged $775,000 in principal under the Note II for the issuance of 479,579 shares of the Company's common stock, par value $0.001 per share to the Lender, On October 20, 2020, the Company exchanged additional $778,252 in principal and coupon interests under Note II for the issuance of 329,768 shares of the Company's common stock, par value $0.001 per share to the Lender, As of the date of this report, the Company has fully repaid the principal and coupon interests of Note II. The Company recorded $38,333 and $35,847 to interest expense from the amortization of debt discount and coupon interest for Note II, respectively, for the three months ended September 30, 2020. The Company recorded $113,750 and $119,811 to interest expense from the amortization of debt discount and coupon interest for Note II, respectively, for the nine months ended September 30, 2020. As of December 31, 2019 and September 30, 2020, accrued coupon interest of $597 and $120,408 on the Note II was included in other payables and accruals (note 13), respectively.

X
- References No definition available. + Details
Name: | cbat_NotesPayableDisclosureTextBlock
Namespace Prefix: | cbat_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_ReceivablesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration